NanoViricides, a development stage company, has reported effectiveness of an anti-influenza drug candidate, under FluCide program, when given orally.
According to the information received from the contract laboratory that performed the studies, namely, KARD Scientific, FluCide drug candidate designed for oral administration has shown strong efficacy in corresponding animal studies.
NanoViricides president Anil Diwan said, "Molecules that nanomedicines are comprised of are notoriously difficult to develop into orally available drugs."
The same lethal animal model, which the company has continued to use for its influenza drug development program was used in the studies.
The company anticipates releasing additional information once the data is analyzed and studied.
NanoViricides CEO Eugene Seymour said an orally administered drug is highly desirable for treating out-patient influenza.
"This will complement our proposed IV piggy-back therapy for the critically ill hospitalized patients. This administration route enables quick and strong response," Seymour added.
